No Clinically Significant Drug Interaction Between Theophylline and Cosentyx
Theophylline does not affect Cosentyx (secukinumab), and these medications can be used together without dose adjustments or special monitoring for drug-drug interactions.
Evidence from FDA Drug Label
The FDA-approved prescribing information for Cosentyx specifically addresses drug interactions with CYP450 substrates. In adult subjects with psoriasis, midazolam (a CYP3A4 substrate) pharmacokinetics were similar when administered alone or following secukinumab administration 1. This demonstrates that secukinumab does not alter the metabolism of drugs processed through the cytochrome P450 system.
Why This Matters for Theophylline
Theophylline is metabolized primarily through the CYP450 enzyme system (particularly CYP1A2, with contributions from CYP2E1 and CYP3A4) 2. Since secukinumab:
- Does not inhibit or induce CYP450 enzymes (as demonstrated by the midazolam study)
- Is a monoclonal antibody that works through immune modulation, not hepatic metabolism
- Has no documented interactions with small molecule drugs metabolized hepatically
There is no mechanistic basis for interaction between these two agents.
Mechanism of Action Considerations
Secukinumab is a human monoclonal antibody targeting IL-17A 3, working through immune pathway modulation rather than affecting drug-metabolizing enzymes. Theophylline acts as a phosphodiesterase inhibitor and adenosine receptor antagonist 2. These completely separate mechanisms of action provide no overlap for potential interaction.
Clinical Practice Implications
- No dose adjustment of either medication is required when used concomitantly
- No additional monitoring beyond standard care for each individual medication is necessary
- Theophylline therapeutic drug monitoring should follow standard protocols (narrow therapeutic window considerations remain unchanged)
- Secukinumab dosing follows standard guidelines for the indication being treated 4
Important Caveats
While there is no drug-drug interaction, clinicians should remain aware that:
- Theophylline has a narrow therapeutic window and multiple other drug interactions with different medications
- Both medications require monitoring for their individual adverse effects (infections with secukinumab; cardiovascular and CNS effects with theophylline)
- The safety considerations for each drug remain independent and unchanged by co-administration